All Articles

A veteran of the disability insurance world is being recognized for decades of commitment to helping individuals and families secure their financial futures. Explore the growing market and the leader’s impact.

Tonix Pharmaceuticals’ FDA-approved TONMYA offers a novel approach to fibromyalgia treatment, targeting sleep disruption and offering a non-opioid alternative. Can it redefine the market?

For 12 years running, PIH Health has been recognized as a leader in digital healthcare. Explore how their commitment to innovation is reshaping patient care and cybersecurity in a rapidly evolving landscape.

Coravin’s new guide isn’t just a directory; it’s a response to evolving consumer tastes – a move towards quality, mindful consumption, and discovering hidden gems in the wine world.

Facing past financial concerns, Assembly Bio has restructured its drug pipeline, secured a significant funding injection, and now projects financial stability into late 2027, focusing on promising antiviral candidates.

Nkarta Inc. is making headway with its novel NK cell therapy for autoimmune diseases, reporting positive early data and a streamlined manufacturing process. However, the company faces growing competition in a rapidly evolving field.

Passage Bio’s PBFT02 shows promise in early trials for FTD, receiving FDA support for broader patient inclusion & securing financial stability. A deeper look at the competitive landscape & patient impact.

Orchestra BioMed is restructuring partnerships and accelerating clinical trials for its innovative bioelectronic hypertension treatment and sirolimus-eluting coronary intervention device, poised to disrupt established markets.

Biotech firm Terns Pharma is pivoting to focus solely on its lead oncology candidate, TERN-701, a novel CML treatment, after discontinuing development of its metabolic disease programs. Early data signals potential for a best-in-class therapy.

Annexon Biosciences is poised for potentially transformative milestones across its neuroinflammatory disease programs – GBS, GA, and CAD – with key regulatory filings and clinical data readouts expected over the next two years.

American Public Education, Inc. anticipates significant EBITDA growth, fueled by strategic focus and robust nursing/veteran programs. Challenges remain in a sector facing increased regulation and competition.

Insurtech firm Management Data Inc. (MDI) expands into the construction industry with Control360, a platform designed to streamline complex financial litigation in construction defect claims, addressing a significant industry pain point.

Mereo BioPharma is making strides in rare bone disease treatment with its lead candidate, setrusumab, and a new partnership focused on autosomal dominant osteopetrosis. A crucial data readout is anticipated in 2026.

Cybersecurity firm Tenable solidifies its position as a leader in the rapidly growing exposure management space, earning top marks from Gartner and reporting strong financial results driven by its innovative platform.

Data analytics firm Health Catalyst strengthens its commitment to patient privacy and security by earning HITRUST certification across key platforms, setting a new standard in healthcare data protection.

Stereotaxis’ GenesisX system promises to overcome longstanding hurdles to robotic surgery adoption – complex installation and high costs. Can this new approach truly democratize access to precision surgical technology?

Online cruise booking platform Cruisebound is shaking up the travel industry with its mobile-first experience and transparent pricing. Fresh funding fuels expansion and innovation in a recovering market.

A legal battle in Louisiana over prison conditions is drawing national attention, with advocates hoping a Supreme Court decision could set a precedent for improved inmate welfare and rights across the US.

A novel approach to hypertension treatment—targeting aldosterone—shows promise with Mineralys Therapeutics’ lorundrostat, potentially offering a lifeline for millions with resistant hypertension and related conditions.

Profound Medical has reclaimed Canadian distribution rights for its innovative prostate treatment system, TULSA-PRO, signaling confidence in the technology and a strategic move to capitalize on growing demand. The move is expected to enhance access to this minimally invasive treatment.